Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Two Companies Form Service Alternative to Traditional CDMOs

By Biodextris | November 30, 2016

Accinov and Biodextris team up to provide a unique contract development and manufacturing service package. 

Accinov of Lyon, France, and Biodextris of Laval, QC, Canada, announced the signing of a co-marketing agreement, presenting customers with an alternative to traditional contract development and manufacturing organizations (CDMO) for the development, production and testing of biopharmaceutical products.

Under the terms of the non-exclusive co-operative agreement, the two companies will work together to co-promote their complementary services to clients in Europe, North America and beyond.

Accinov will be able to present clients to Biodextris’ process development, analytical development and cGMP QC testing services, while Biodextris can introduce clients to Accinov’s flexible, ready-to-use cGMP biomanufacturing environment and associated quality assurance services.

Clients will benefit from a seamless customer experience thanks to the coordinated approach, aligned expertise and shared focus on delivering integrated solutions for clients developing innovative biologic products.

“We are excited to enter this agreement with Accinov, who are pioneering a biomanufacturing model unique in the pharmaceutical and biotechnology industries,” said Joseph Zimmermann, Biodextris president and CEO. “This strategic collaboration reflects our commitment to providing a full-spectrum service offering and broadening the competitive advantage customers realize working with our organizations.”

“The Biodextris team’s history of advancing vaccine and biologic products to the clinic and the Accinov team’s expertise are complementary and self-reinforcing,” said André Dupont, Accinov president. “Together we establish a wholly flexible solution for the development and GMP manufacturing of new biopharmaceuticals.”

(Source: PR Newswire)

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Prolific Machines logo.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE